Skip to main content
padlock icon - secure page this page is secure

Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies

Buy Article:

$59.00 + tax (Refund Policy)

Abstract Objectives: 

The therapy of advanced, relapsed or refractory primary cutaneous lymphomas is often unsatisfactory. Recent data indicate a favourable pharmacokynetic, pharmacodynamic and toxicity profile of pegylated liposomal doxorubicin (Peg-Doxo) in primary cutaneous T-cell lymphomas, while in primary cutaneous B-cell lymphomas (PCBCLs), the drug efficacy has never been assessed so far. Methods: 

We performed a prospective phase II pilot clinical trial of Peg-Doxo monotherapy (20 mg/m2) in PCBCLs. One patient had a marginal zone B-cell lymphoma and four were affected by diffuse large B-cell lymphoma-leg type, all with widespread nodular lesions. Results: 

All the patients achieved a complete response (CR = 100%) in a short period of time (median 3 months), even when pretreated with radio-chemotherapy. Two experienced a relapse. At follow-up, one patient died for progressive disease; four are in CR after 5, 52, 63 and 69 months. As concerning the toxicity profile, the treatment was well-tolerated, no one decreased or delayed the dose. The haematological toxicity was mild with only one case of grade III neutropenia; a patient showed a grade I neurotoxicity. Dermatological toxicity, in particular the palmar–plantar erythrodysesthesia, did not occurred, probably because of both the low dosages of Peg-Doxo monotherapy and the oral prophylaxis with pyridoxine. Conclusions: 

In spite of the small number of patients, it emerges that monochemotherapy with Peg-Doxo has a significantly high clinical activity and a good safety profile in PCBCLs, even in aggressive forms, compared with other therapeutic regimens, which are completely reviewed. It suggests the need of further investigations in this field.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: monochemotherapy; pegylated liposomal doxorubicin; primary cutaneous B-cell lymphomas; primary cutaneous lymphomas

Document Type: Research Article

Affiliations: 1: Clinical Hematology, Department of Hematology, ‘Spirito Santo’ Civic Hospital, Pescara, Italy 2: Clinic of Hematology, Polytechnic University of Marche, Ancona, Italy 3: Institute of Pathology, Polytechnic University of Marche, Ancona, Italy 4: Department of Dermatological Sciences, University of Florence, Florence, Italy 5: Department of Hematology, University of Florence, Florence, Italy 6: Division of Dermatology, Macerata, Italy 7: Division of Internal Medicine, Civitanova Marche, Italy

Publication date: March 1, 2009

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more